Agios Pharmaceuticals, Inc. (AGIO)
33.31
-0.01
(-0.03%)
USD |
NASDAQ |
Aug 31, 15:00
Agios Pharmaceuticals Research and Development Expense (Annual) : 334.36M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 334.36M |
| December 31, 2024 | 295.63M |
| December 31, 2023 | 288.90M |
| December 31, 2022 | 271.35M |
| December 31, 2021 | 247.73M |
| December 31, 2020 | 211.02M |
| December 31, 2019 | 402.81M |
| December 31, 2018 | 341.32M |
| Date | Value |
|---|---|
| December 31, 2017 | 292.68M |
| December 31, 2016 | 220.16M |
| December 31, 2015 | 141.83M |
| December 31, 2014 | 100.37M |
| December 31, 2013 | 54.50M |
| December 31, 2012 | 41.04M |
| December 31, 2011 | 31.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Biogen, Inc. | 1.481B |
| Insmed, Inc. | 771.09M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Exelixis, Inc. | 825.00M |